IRIS
FORNARO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.993
EU - Europa 1.665
AS - Asia 1.498
SA - Sud America 368
Continente sconosciuto - Info sul continente non disponibili 238
AF - Africa 93
OC - Oceania 4
Totale 6.859
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.845
SG - Singapore 678
IT - Italia 631
BR - Brasile 276
DE - Germania 227
CN - Cina 219
RU - Federazione Russa 199
FI - Finlandia 157
HK - Hong Kong 143
SE - Svezia 137
VN - Vietnam 110
FR - Francia 109
CA - Canada 75
GB - Regno Unito 74
BD - Bangladesh 66
IN - India 62
AR - Argentina 38
JP - Giappone 34
ZA - Sudafrica 31
CI - Costa d'Avorio 27
IQ - Iraq 25
ID - Indonesia 23
PL - Polonia 23
TR - Turchia 23
NL - Olanda 21
MX - Messico 20
PK - Pakistan 19
EC - Ecuador 18
SA - Arabia Saudita 15
AT - Austria 14
BE - Belgio 14
PH - Filippine 13
VE - Venezuela 11
CO - Colombia 9
LT - Lituania 9
TT - Trinidad e Tobago 9
UA - Ucraina 9
GT - Guatemala 8
UZ - Uzbekistan 8
CR - Costa Rica 7
CZ - Repubblica Ceca 7
ES - Italia 7
IR - Iran 7
JM - Giamaica 7
MY - Malesia 7
AM - Armenia 6
CL - Cile 6
KE - Kenya 6
MA - Marocco 6
SV - El Salvador 6
TN - Tunisia 6
KZ - Kazakistan 5
PY - Paraguay 5
TH - Thailandia 5
AU - Australia 4
CH - Svizzera 4
CW - ???statistics.table.value.countryCode.CW??? 4
HN - Honduras 4
IE - Irlanda 4
IL - Israele 4
PR - Porto Rico 4
AE - Emirati Arabi Uniti 3
CG - Congo 3
ET - Etiopia 3
KG - Kirghizistan 3
LB - Libano 3
NI - Nicaragua 3
SI - Slovenia 3
AL - Albania 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BH - Bahrain 2
DK - Danimarca 2
EE - Estonia 2
EG - Egitto 2
GP - Guadalupe 2
KR - Corea 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
TW - Taiwan 2
ZW - Zimbabwe 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
BS - Bahamas 1
CM - Camerun 1
GF - Guiana Francese 1
HR - Croazia 1
HT - Haiti 1
JO - Giordania 1
KW - Kuwait 1
MK - Macedonia 1
MR - Mauritania 1
MT - Malta 1
MU - Mauritius 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 6.619
Salva come PNG Salva come JPEG
Città #
Ashburn 464
Singapore 391
San Jose 281
Chandler 170
Milan 168
Hong Kong 143
Munich 138
Helsinki 120
Fairfield 115
Nyköping 114
Beijing 101
Council Bluffs 96
Los Angeles 72
Dallas 70
New York 66
Houston 62
Rome 55
Lauterbourg 53
Cambridge 50
Bari 44
Woodbridge 43
Moscow 41
Seattle 41
Santa Clara 40
Columbus 37
Wilmington 36
Ho Chi Minh City 34
Falkenstein 33
São Paulo 32
Ann Arbor 28
Boardman 28
Abidjan 27
Hanoi 27
Lawrence 26
Figino 25
Buffalo 23
Chicago 23
Phoenix 23
Turku 22
Tokyo 20
Warsaw 20
Montreal 19
Frankfurt am Main 18
Inglewood 18
Roxbury 18
Toronto 18
Denver 17
Johannesburg 17
London 16
Naples 15
San Francisco 15
Atlanta 14
Brooklyn 14
Brussels 14
North Bergen 14
Des Moines 13
Florence 12
Poplar 12
El Paso 11
Jakarta 11
Turin 11
Orem 10
Stockholm 10
Manchester 9
Mexico City 9
Paris 9
Pittsburgh 9
Princeton 9
Amsterdam 8
Bacolod City 8
Baghdad 8
Boston 8
Chennai 8
Dhaka 8
Jyväskylä 8
Mumbai 8
Pescara 8
Queens 8
Quito 8
Washington 8
Brasília 7
Nuremberg 7
Rio de Janeiro 7
Riyadh 7
Ankara 6
Bengaluru 6
Lahore 6
Newark 6
Redwood City 6
Salt Lake City 6
San Antonio 6
Shanghai 6
Tampa 6
Tashkent 6
Vienna 6
Yerevan 6
Belo Horizonte 5
Bologna 5
Caracas 5
Da Nang 5
Totale 3.980
Salva come PNG Salva come JPEG
Nome #
Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients 280
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 204
Clinical, histologic and prognostic features of clinically amyopathic dermatomyositis 202
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis 202
Anti-SAE dermatomyositis: clinical and histologic characteristics from a monocentric Italian cohort 200
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 186
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 176
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases 172
Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy 171
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 152
Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis 144
The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients 142
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 134
Sindrome anti-sintetasi: due casi di anti-EJ (anti-glycyl-tRNAsintetasi) 133
Body mass index and adipokines/cytokines dysregulation in systemic sclerosis 130
The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment 129
Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings 128
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors 122
Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study 118
Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis 116
High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry 112
Cartilage damage: clinical approach 111
A Machine Learning Approach for Predicting Sustained Remission in Rheumatoid Arthritis Patients on Biologic Agents 110
Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity 109
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis 109
Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients 109
Elevated Expression of ADAM10 in Skeletal Muscle of Patients with Idiopathic Inflammatory Myopathies Could Be Responsible for FNDC5/Irisin Unbalance 109
Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis 108
Complete Hydatidiform Mole Mimicking Sacroiliitis 108
Preliminary data on post market safety profiles of covid 19 vaccines in rheumatic diseases: Assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: A two-centers study 105
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis 103
Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering 102
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus 101
Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is highly expressed in CD14+ circulating cells of scleroderma patients 101
Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis 100
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors 98
Effectiveness of Tapering Rituximab Dose in Idiopathic Inflammatory Myopathies: Real-World Data from a Monocentric Study 95
Long-term safety of rituximab in rheumatic patients with previously resolved hepatitis B virus infection 93
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study 85
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 81
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry 80
Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10-year study from the BIOPURE registry 80
Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases 79
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 79
Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry 76
The impact of multimorbidity on QoL in inflammatory myopathies: COVAD cluster analysis 76
Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review 74
Erratum: Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus (Rheumatology (2020) 59 (1188) DOI: 10.1093/rheumatology/kez442) 74
Histopathologic Features of Fibrotic Knee Synovitis in a Young Adult with Seronegative Rheumatoid Arthritis 72
Letters to the editors 71
Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre 67
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course 63
Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies 63
Power Doppler signal at the enthesis and bone erosions are the most discriminative OMERACT ultrasound lesions for SpA: results from the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) multicentre study 57
Paradoxical Pustular Psoriasis in a Patient with Psoriatic Arthritis on Secukinumab Treatment 56
Predictors of long-term clinical remission in rheumatoid arthritis 45
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study 44
Integrating large language models in medicine: a study of Claude 2’s performance in MDAAT scoring for idiopathic inflammatory myopathies 42
Mobile session fixation attack in micropayment systems 40
Neuropathic pain in spondyloarthritis: Decoding its prevalence, risk factors, and impact on disease activity 38
Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study 37
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry 36
Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK Inhibitors 35
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry 33
Aquaporin-4 downregulation in dysphagic patients with idiopathic inflammatory myopathies: myofiber vulnerability and inflammation drivers 32
Response to: ‘Response to: “Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients” by Fornaro et al‘ by Agca et al 29
Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the biologic apulian registry (BIOPURE) 27
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project 18
Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients 16
Sjögren’s disease and concomitant fibromyalgia: clinical profile and implications for disease activity assessment 15
Dermatomyositis is characterized by TYK2-dependent STAT3 activation 15
Totale 6.859
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.297
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.297
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022200 0 0 0 0 9 11 25 14 17 30 32 62
2022/2023455 46 76 30 31 30 69 9 66 61 6 19 12
2023/2024221 17 45 13 19 13 41 9 6 3 7 3 45
2024/20251.364 42 13 62 26 25 136 188 247 65 95 174 291
2025/20263.123 388 151 218 350 415 170 284 105 304 307 106 325
2026/2027996 127 133 222 481 33 0 0 0 0 0 0 0
Totale 6.859